Baseline evaluations of liver laboratory assessments are recommended. APTIOM need to be discontinued in patients with jaundice or other proof of important liver harm.diazepam will raise the level or effect of ruxolitinib by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Importance Unidentified.Reserve concomitant prescribing o